Gran Colombia Gold Corp. (TPRFF) Financials Nov 14, 2014,
Gran Colombia Gold Corp. (TPRFF) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Gran Colombia Gold Corp.
Fiscal year is January-December. All values CAD millions. 2010 2011 2012 2013 5-year trend
Sales/Revenue - 20.78M 136.25M 168.18M 153.04M
Cost of Goods Sold (COGS) incl. D&A - 24.85M 125.07M 150.21M 154.17M
COGS excluding D&A - 21.3M 106.99M 133.35M 137.05M
Depreciation & Amortization Expense - 3.55M 18.08M 16.85M 17.12M
Depreciation - 3.55M 18.08M 16.85M 17.12M
Amortization of Intangibles - - 0 0 0
Gross Income - (4.07M) 11.18M 17.98M (1.13M)
2010 2011 2012 2013 5-year trend
SG&A Expense - 14.22M 27.77M 20.05M 13.38M
Research & Development - 0 0 0 0
Other SG&A - 14.22M 27.77M 20.05M 13.38M
Other Operating Expense - 0 0 0 138,072
Unusual Expense - 0 (5.35M) 14.33M 156.78M
EBIT after Unusual Expense - 0 5.35M (14.33M) (156.78M)
Non Operating Income/Expense - 99,912 (12.53M) (6.5M) 1.64M
Non-Operating Interest Income - 156,564 91,023 226,921 186,500
Equity in Affiliates (Pretax) - 0 0 0 0
Interest Expense - 627,285 7.7M 16.49M 15.07M
Gross Interest Expense - 627,285 7.7M 16.49M 21.87M
Interest Capitalized - 0 0 0 6.8M
Pretax Income - (18.67M) (31.37M) (39.16M) (184.68M)
Income Tax - (1.25M) 4.9M (3.25M) (14.65M)
Income Tax - Current Domestic - - 3.43M 3.09M (166,923)
Income Tax - Current Foreign - - 0 0 0
Income Tax - Deferred Domestic - - 1.47M (6.35M) (14.49M)
Income Tax - Deferred Foreign - - 0 0 0
Income Tax Credits - - 0 0 0
Equity in Affiliates - 0 0 0 0
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income - (17.42M) (36.27M) (35.91M) (170.02M)
Minority Interest Expense - 0 380,914 248,913 152,498
Net Income - (17.42M) (36.65M) (36.16M) (170.18M)
Extraordinaries & Discontinued Operations - 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets - 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations - 0 0 0 0
Net Income After Extraordinaries - (17.42M) (36.65M) (36.16M) (170.18M)
Preferred Dividends - 0 0 0 0
Net Income Available to Common - (17.42M) (36.65M) (36.16M) (170.18M)
EPS (Basic) - (4.64) (2.97) (2.25) (11.14)
Basic Shares Outstanding - 3.66M 12.51M 15.28M 15.28M
EPS (Diluted) - (4.64) (2.97) (2.25) (11.14)
Diluted Shares Outstanding - 3.66M 12.51M 15.28M 15.28M
EBITDA - (14.75M) 1.5M 14.78M 2.47M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...
Continue Reading
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...
Continue Reading
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...
Continue Reading
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Top 5 Most Recently Viewed Articles
Grand Circle Cruise Line Recognized Among the Best Grand Circle Cruise Line (GCCL) recently earned the impressive title of #2 Best River Cruise Line in the Travel + Leisure's 2025 World's Best Awards. This accolade showcases the hard work and dedication of the teams and crew members who make each journey remarkable along Europe’s scenic rivers. Celebrating a Special...
Continue Reading
Lancaster Resources Secures Approval for Exploration License Vancouver-based Lancaster Resources Inc. (CSE:LCR) (OTC:LANRF) (FRA:6UF0) is pleased to announce a significant milestone in its gold exploration journey. The company has received confirmation of an Exploration License for the Lake Cargelligo Gold Project from the State of New South Wales. Covering an impressive...
Continue Reading
Understanding the Vitrectomy Devices Market Growth The vitrectomy devices industry has become increasingly vital in treating various eye-related disorders, with significant growth projected in the coming years. By focusing on technological advancements and heightened awareness of eye health, the market is set to expand impressively. According to a recent report, the...
Continue Reading
Understanding RDG Mining's Latest Offerings In recent times, the popularity of cryptocurrency has surged significantly, with platforms like RDG Mining capitalizing on this trend. RDG Mining is a leading cloud mining service based in the UK that has captured the interest of over 7.5 million users globally, particularly with the rise in various cryptocurrencies, including...
Continue Reading
Revisions to Financial Reporting and Calendar The board of Pharma Equity Group A/S has recently made the strategic decision to submit only half-yearly financial reports moving forward. This adjustment reflects a shift in focus towards more impactful reporting. As a result, the financial calendar for 2025 has been updated to better align with these new reporting practices....
Continue Reading